Print  |  Close

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas


Active: Yes
Cancer Type: Hematopoietic Malignancies
Lymphoma
Non-Hodgkin Lymphoma
Solid Tumor
Unknown Primary
NCT ID: NCT04104776
Trial Phases: Phase I
Phase II
Protocol IDs: 0209-01 (primary)
NCI-2020-01007
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Constellation Pharmaceuticals
NCI Full Details: http://clinicaltrials.gov/show/NCT04104776

Summary

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in
patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of
EZH2.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.